Meeting
2022 ASCO Annual Meeting
A study of relacorilant in combination with nab-paclitaxel in patients with metastatic pancreatic ductal adenocarcinoma.
Authors
Erkut Hasan Borazanci
HonorHealth, Scottsdale, AZ
Erkut Hasan Borazanci , Nathan Bahary , Paul Eliezer Oberstein , Vincent Chung , Roland T. Skeel , E. Gabriela Chiorean , Andrew E Greenstein , Hristina I Pashova , Iulia Cristina Tudor , Grace Mann
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Pancreatic Cancer
Clinical Trial Registration Number
NCT04329949
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 4140)
DOI
10.1200/JCO.2022.40.16_suppl.4140
Abstract #
4140
Poster Bd #
126
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Gastrointestinal Cancers Symposium
A phase I/II study of antroquinonol in combination with nab-paclitaxel and gemcitabine for patients with metastatic pancreatic cancer.
First Author: Yan-Shen Shan
Poster
2022 ASCO Annual Meeting
Trial in progress: Phase I study of SY-5609, a potent, selective CDK7 inhibitor, with initial expansion in adults with metastatic pancreatic cancer.
First Author: Manish Sharma
Poster
2019 Gastrointestinal Cancers Symposium
GA CPI 613: A single arm, open-label phase I study of CPI-613 in combination with gemcitabine and nab-paclitaxel for patients with locally advanced or metastatic pancreatic cancer.
First Author: Angela Tatiana Alistar
Poster
2015 Gastrointestinal Cancers Symposium
The value of tissue protein expression as a predictor of efficacy for first or second-line therapy (tx) in metastatic ductal pancreas cancer (PDAC) in patients (pts) receiving either gemcitabine (G)-based tx or 5FU (F)-based tx.
First Author: Lauren Carcas